Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nyxol to Reverse Pharmacologically Induced Mydriasis in Healthy Pediatric Subjects
NCT05223478Phase 3Completed
- Sponsor
- Opus Genetics
- Start
- Dec 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Mydriasis comparing Phentolamine Ophthalmic Solution 0.75% with Phentolamine Ophthalmic Solution Vehicle (2 arms). Primary endpoints: Safety Measurements at 24 Hours, Vital Signs at 24 Hours and 1 more. Started Dec 2021; status: completed.
02
Drugs
phentolamine
03
Conditions
Mydriasis
Beyond the preview
Go deeper on NCT05223478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05223478.